Thrombocytopenia Up With Use of Phosphate-Buffered Tirofiban

Share this content:
Thrombocytopenia Up With Use of Phosphate-Buffered Tirofiban
Thrombocytopenia Up With Use of Phosphate-Buffered Tirofiban

TUESDAY, Aug. 16, 2016 (HealthDay News) -- For patients with acute coronary syndrome, phosphate-buffered tirofiban, but not citrate-buffered tirofiban, is associated with an increased risk of thrombocytopenia, according to a study published in the Aug. 22 issue of JACC: Cardiovascular Interventions.

Marianna Adamo, M.D., from Erasmus Medical Center in Rotterdam, Netherlands, and colleagues randomized 3,232 patients to receive tirofiban or unfractionated heparin (UFH). A total of 879 patients were allocated to phosphate-buffered tirofiban and 874 to the UFH group in the early phase, and 737 and 742 patients were treated with citrate-buffered tirofiban and UFH, respectively, in the late phase.

The researchers found that patients treated with phosphate-buffered tirofiban had an increased relative risk for thrombocytopenia in the early phase (odds ratio, 3.51 [95 percent confidence interval (CI), 1.15 to 10.73] for nadir <90,000/mm³; odds ratio, 2.83 [95 percent CI, 1.11 to 7.22] for nadir <100,000/mm³). The relative risk was not increased for patients treated with citrate-buffered tirofiban in the late phase (odds ratios, 1.01 [95 percent CI, 0.20 to 5.05] and 0.99 [95 percent CI, 0.26 to 3.45], respectively). The randomization period significantly modified the effect of the treatment on platelet decrease (P for interaction = 0.024).

"Phosphate-buffered tirofiban, currently marketed as a generic drug, is associated with a higher rate of thrombocytopenia with a potentially increased risk for adverse clinical outcomes compared with citrate-buffered tirofiban," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NTproBNP Levels Are Significantly Lower in Blacks

NTproBNP Levels Are Significantly Lower in Blacks

Higher NTproBNP levels linked to increased risk of death; this association did not differ by race

Data May Weigh on Pros/Cons of Expanded Care Optometry

Data May Weigh on Pros/Cons of Expanded Care ...

Majority of residents in Kentucky, Oklahoma, New Mexico live within 30 minutes of ophthalmologist

Gaps Seen Between Hearing Loss, Receipt of Medical Evaluation, Tx

Gaps Seen Between Hearing Loss, Receipt of Medical ...

About 20.6 percent of those with hearing less than excellent/good had visited doctor for hearing issues

is free, fast, and customized just for you!

Already a member?

Sign In Now »